Japanese pharmaceutical company Shionogi’s new oral COVID-19 drug has achieved the primary endpoint in a clinical trial, the company announced in September. From February to July, Shionogi conducted a clinical trial with 1,821 people to evaluate ensitrelvir fumaric acid (S-217622), the oral drug the company developed in February. The subjects were not at risk for other…

TOKYO—An experimental treatment from Shionogi & Co. Ltd. has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drug maker said on Sunday. The pill, S-217622, “demonstrated rapid clearance of the infectious SARS-CoV-2 virus”, Shionogi said in a statement, citing Phase-2b results from the Phase II/III clinical trial of…

Shionogi & Co. stock slumped 16 percent in Tokyo after preclinical studies showed its experimental COVID-19 drug disturbed fetal development, triggering concerns about its approval. Kyodo News reported that the drug likely wouldn’t be recommended for pregnant women without giving attribution. The animal data, which showed harm when given at high doses, was submitted to Japanese…

TOKYO—Drugmaker Shionogi & Co. Ltd. has applied for approval to make and sell its oral COVID-19 treatment in Japan, the firm said on Friday. Known as S-217622, the drug would become the country’s third antiviral pill approved for coronavirus patients, following those developed by Pfizer Inc. and Merck & Co.. In a statement, Shionogi said…

TOKYO—Japan’s Shionogi & Co. Ltd announced on Monday that phase III of its clinical trial for a new COVID-19 vaccine has begun in Vietnam. The pharmaceutical company has already conducted clinical trials in Japan, but had said previously they will conduct multiple trials globally as well.